PubMed Health⌕ Search

Biomedical subjects

K Fuse

Publications and source records attributed to K Fuse.

At least 109 records · Page 6Linked to original sources
PubMed1988

[Morphometrical study on prognosis of stage I pulmonary adenocarcinoma].

The prognostic significance of morphometry in stage I pulmonary adenocarcinoma had been examined in Papanicolaou-stained bronchial brushings, using an image analyzer. The data of long-term survivors (LTS), alive for more than 5 years, and short-term survivors (STS), who had died within 5 years, were compared. LTS were found to have a smaller nuclear area, a shorter nuclear perimeter, and a smaller nucleolar area than those of the STS. The nuclear size is considered important in any histological subtypes. The variation index of the nuclear area, the nuclear circularity, and the number of nucleoli did not differ between the two groups. These results would seem to be useful in determining the prognosis and the indication type of adjuvant therapy to be used in surgical operations.

Adenocarcinoma↗
PubMed1988

[A case of A-V fistula with severe hemolysis following internal jugular venipuncture].

Severe hemoglobinuria was observed in a case with abdominal aortic aneurysm on the 23rd postoperative day. The typical continuous murmur was heard on the right upper chest, and IADSA revealed an A-V fistula connecting between the right subclavian artery and the internal jugular vein. This A-V fistula was thought to have been caused by an inadvertent arteriopuncture during the central venous cannulation at the time of the operation. Poloxamer 188 (a non-ionic surfactant) and haptoglobin were given intravenously, and they proved to be quite effective in improving intravascular mechanical hemolysis and hemoglobinuria. A division of the A-V fistula was done successfully, which was facilitated by the median sternotomy combined with the extension of the skin incision to the neck. It cannot be overemphasized that utmost care should be taken to prevent any complication at the time of the central venous cannulation.

Anemia, Hemolytic↗
PubMed1988

[Bacterial intracranial aneurysms associated with infectious endocarditis--report of 3 cases].

Three cases of bacterial intracranial aneurysms associated with infective endocarditis are reported. All of the patients were successfully treated by various combinations of cardiac surgery, neurosurgery and chemotherapy with antibiotics. Case 1: A 39-year-old female was admitted with the complaint of sudden onset of severe headache following persistent fever of several month's duration. CT scan revealed a left frontal old hematoma and angiography detected an aneurysm located in the frontal ascending branch of the left middle cerebral artery. After 2 weeks' antibiotic therapy, the second angiography showed the aneurysm to be decreased in size. The third angiography, performed 2 weeks after cardiac valve replacement for infective endocarditis, demonstrated complete resolution of the aneurysm. Case 2: A 19-year-old male entered hospital with high fever and chills. In addition to infective endocarditis, CT scan and angiography revealed an aneurysm arising from the distal portion of the left posterior cerebral artery. The patient was treated with high dose antibiotics and then his general condition improved. However, angiography examined 4 weeks after the initial study demonstrated the aneurysm to be apparently enlarged. Therefore, the aneurysm was excised before cardiac surgery. Repeated angiography after valve replacement showed no further aneurysm. Case 3: A 30-year-old female was admitted on the diagnosis of infective endocarditis and meningitis. CT scan showed abnormal density areas in the right frontal lobe and the left temporal lobe.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1986

[Host factors in cancer chemotherapy].

Cancer grows in interaction with the host, that is, a host-tumor relationship exists. Investigations of host factors in patients receiving cancer chemotherapy are important, as they reveal the conditions in which a tumor response can develop. Furthermore, reliable host factors, if present, will be useful for quantitative evaluation of the effects of treatment. We have investigated the following three categories of host factors in relation to the effects of cancer chemotherapy and/or immunotherapy. CBC, and blood chemistries (44 parameters). Tumor markers; sialic acid, RNase, lysozyme, ferritin, IAP (immunosuppressive acidic protein), elastase I, AFP, CEA, POA, CA 19-9, CA 125, etc. Immunological parameters; lymphocyte, active T cell, T cell, B cell, IgG Fc receptor-positive T cell, lymphocyte blastogenesis stimulated by PHA, or concanavalin-A, ADCC activity, interferon production in vitro induced by poly I: C, or PHA, PPD skin test, immune complex, immunoglobulin G, A, and M, OKT series 3, 4, 8, 11, 4/8 ratio, antihuman HLA-DR, Leu 11, NK cell activity, etc. From our clinical observations, there were no significant differences in the pretreatment levels of these parameters between responders and non-responders. In responders, there was a tendency for the host factors to show greater degrees of improvement following treatment than in non-responders, but none proved to be reasonably reliable parameters for evaluating therapeutic effects. On the other hand, from our clinical observations on the advanced gastric cancer cases, life span showed a close correlation with tumor regression induced by cancer chemotherapy. Because of these facts, it is only natural that the clinical effects of chemotherapy are currently determined by definite tumor regression.

Humans↗
PubMed1984

[Pharmacokinetics of human interferons].

Interferon in the blood was rapidly cleared from the circulation after intravenous injection. Intramuscular injection of alpha-interferon caused low but stable interferon levels in the blood. However, in the case of beta-interferon, interferon was never detected consistently in the blood after intramuscular or subcutaneous administration. Intraarterial administration of beta-interferon also caused low but stable interferon levels in the blood. Our studies suggest that beta-interferon should be given intravenously to see clinical beneficial. No difference in pharmacokinetics was seen between natural interferon and recombinant interferon. No difference was also noted between partially purified interferon and highly purified interferon.

Animals↗
PubMed1983

[Phase II clinical trial of MCNU].

MCNU is a new derivative of nitrosourea and experimental studies have shown equal or superior activity to known nitrosourea compounds. Twenty one cases were entered into our clinical studies with a phase II study. Nineteen cases have had a several courses of prior chemotherapy. Four out of 21 cases achieved a partial response (each one of lymphoepithelioma, parotid gland cancer, recurrent uterine cancer and recurrent breast cancer). The major toxicity encountered during treatment was myelosuppression. Full recovery of myelosuppression was delayed and was seen six to eight weeks after each injections. These initial results justify further clinical investigations with MCNU.

Adolescent↗
PubMed1983

[Pancreatic oncofetal antigen (POA)].

Recently, there has been an increasing interest in the diagnostic and prognostic usefulness of tumor-associated antigen of embryonic and fetal origin. Many approaches have been attempted to make an early diagnosis of the pancreatic cancer, where a specific screening blood test for the pancreatic cancer is required. By using antiserum to fetal pancreas, Banwo et al, discovered an oncofetal antigen that was present in human fetal pancreas, pancreatic tumor tissue, and sera from patients with the pancreatic cancer. Pancreatic oncofetal antigen (POA) was considered to be an oncofetal antigen for human pancreas, and its measurement seemed to be useful in the diagnosis of pancreatic cancer. But elevated levels of POA were also observed in the serum of some patients with cancer of the stomach, lung, colon, or liver as well as in the serum of some pregnant women and others with certain benign conditions. In summary, combined assay with various tumor markers was considered to be useful for the diagnosis of pancreatic cancer.

Antigens, Neoplasm↗
PubMed1982

[Clinical experiences with pepleomycin].

From experimental observations, Peplomycin was expected to be more active against a variety of tumors and to be less toxic for the lung than the parent compound. An intermittent dose(10mg. twice a week) of peplomycin was tested in patients with malignant lymphoma or squamous cell carcinoma who had failed conventional treatment. There were two cases of CR and five cases of PR in twelve cases with malignant lymphoma, and two cases of PR in fourteen cases with squamous cell carcinoma. Out of 26 cases treated with peplomycin, fever was seen in ten cases(38.5%) and pulmonary complication was seen in five cases (19.2%). These data obtained from peplomycin treatment were compared with the results obtained from our previous experiences with bleomycin. Response rate, spectrum and frequency of side reactions of peplomycin treatment were substantially identical with those of bleomycin treatment. However, remission duration and life span were much longer in peplomycin treatment. In this respect, peplomycin seems to be superior than bleomycin to a certain extent.

Adult↗